Program
CPO-107
Also written as “CPO107”, “JMT601 Injection” and “JMT601”.
Its studies are mostly in Lymphoma, Non-Hodgkin · Glomerulonephritis, Membranous · Lymphoma, B-Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 22 open or running | phase 2since Jun 11, 2025 | Jul 19, 2023 | Apr 1, 2027phase 2 · NCT07029139 |
| Conjupro Biotherapeutics | 10 open or running | phase 1since Mar 2, 2021 | Mar 2, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2021First study: phase 1 study in Lymphoma, Non-HodgkinNew to Conjupro BiotherapeuticsConjupro Biotherapeutics · NCT04853329 · 7 enrolled · United States
- Jul 19, 2023CSPC Pharmaceutical Group's first study: phase 1 study in Lymphoma, B-CellNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06725524 · 186 planned · China
- Jun 11, 2025Phase 2 study in Primary Membranous NephropathyCSPC Pharmaceutical Group · NCT07029139 · 156 planned
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Primary Membranous NephropathyCSPC Pharmaceutical Group · NCT07029139
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07029139Primary Membranous Nephropathy | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 1, 2027 | 156 |
| NCT06725524Lymphoma, B-Cell · China | 1 | Recruiting | CSPC Pharmaceutical Group | Dec 31, 2025 | 186 |
| NCT04853329Lymphoma, Non-Hodgkin · United States | 1 | Terminated | Conjupro Biotherapeutics | Jan 31, 2023 | 7 |
How it is read
Names in the registry
- “CPO107”, 1 entry
- “JMT601 Injection”, 1 entry
- “JMT601”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 1 study
- Glomerulonephritis, Membranous, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.